Design Therapeutics Begins Patient Dosing of DT-818 in Phase 1 Trial for Myotonic Dystrophy

Design Therapeutics, Inc. (NASDAQ: DSGN), a clinical-stage biotechnology company, announced the initiation of patient dosing in its Phase 1 multiple-ascending dose trial of DT-818 on June 30, 2026. The candidate is being evaluated in adults with myotonic dystrophy type-1 (DM1). Shares rose as much as 5.2% following the announcement. With dosing now underway, the GeneTAC® platform has its third clinical-stage program actively enrolling patients.

A Genetic Disease With No Disease-Modifying Treatment

Myotonic dystrophy type-1 is a progressive, monogenic, autosomal dominant disease that affects skeletal muscle, the heart, the brain, and other organs. Patients commonly experience muscle weakness, myotonia (delayed muscle relaxation), and early-onset cataracts. Beyond that, many also develop cardiac arrhythmias and changes in neuropsychological function as the disease advances. DM1 is estimated to affect more than 70,000 people in the United States. Despite that prevalence, no approved therapy currently addresses the underlying genetic cause of the disease; existing care is limited to managing individual symptoms as they emerge.

How DT-818 Targets the Root Cause of DM1

DM1 is caused by an abnormal CTG repeat expansion within the DMPK gene. This expanded repeat produces toxic RNA that accumulates inside the cell nucleus, forming clusters known as nuclear foci. These foci disrupt the normal splicing of numerous other genes, which in turn drives the disease’s wide-ranging symptoms across muscle, heart, and brain tissue. DT-818 is a GeneTAC® small molecule engineered to selectively reduce transcription of the mutant DMPK allele while sparing the healthy copy of the gene. By dialing down production of the toxic RNA at its source, the molecule is designed to address DM1’s underlying genetic cause rather than simply manage its downstream symptoms.

Preclinical Data Pointed to a Best-in-Disease Profile

Design Therapeutics nominated DT-818 as a development candidate after a substantial body of preclinical work. In patient-derived DM1 cells, the molecule achieved a greater than 90% reduction in toxic RNA foci, along with corresponding splicing correction and selective targeting of the mutant allele. The company has also reported broad tissue distribution in preclinical models, an important attribute given that DM1 affects multiple organ systems simultaneously. Taken together, this profile is what led Design to describe DT-818 as a potentially best-in-disease candidate ahead of entering the clinic.

Trial Design and the Road to 2027 Data

The current study is an open-label, multiple-ascending dose Phase 1 trial. Its purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of DT-818 in adults with DM1. Design previously obtained ex-U.S. regulatory clearance and structured the trial to run in Australia, where it will assess both safety and the correction of mis-splicing. Pratik Shah, Ph.D., chairperson and chief executive officer of Design Therapeutics, called the start of dosing an important milestone for the company and for the DM1 community. Data from the study are anticipated in 2027, a timeline the company has consistently maintained since first announcing the program.

Positioning Within the Broader GeneTAC® Pipeline

DT-818 is the third program from Design’s GeneTAC® platform to reach clinical-stage development. The platform is built around small molecules that are designed to dial gene expression up or down without relying on gene editing or exogenous gene delivery. In addition to DT-818, the company is advancing DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, with results from the Friedreich ataxia program expected later this year. Design is also conducting early discovery work in Huntington’s disease, a fourth indication tied to the same repeat-expansion biology that underlies its existing pipeline. As a result, today’s dosing milestone extends a platform validation story that spans several distinct, high-burden genetic diseases.

Strategic Investment Summary

• Clinical Milestone: Design Therapeutics (NASDAQ: DSGN) began patient dosing in its Phase 1 multiple-ascending dose trial of DT-818 for myotonic dystrophy type-1 on June 30, 2026, sending shares up as much as 5.2%.
• Mechanism: DT-818 is a GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele, targeting the genetic root cause of DM1 rather than its downstream symptoms.
• Preclinical Strength: In patient-derived cells, DT-818 achieved a greater than 90% reduction in toxic RNA foci along with corresponding splicing correction, supporting its potential best-in-disease profile.
• Unmet Need: DM1 affects more than 70,000 people in the United States and currently has no approved disease-modifying treatment, leaving a substantial commercial opportunity for an effective therapy.
• Trial Design: The open-label Phase 1 MAD study is evaluating safety, tolerability, pharmacokinetics, and correction of mis-splicing, with topline data anticipated in 2027.
• Pipeline Depth: DT-818 is the third clinical-stage GeneTAC® program, joining DT-216P2 in Friedreich ataxia and DT-168 in Fuchs endothelial corneal dystrophy, alongside earlier-stage work in Huntington’s disease.
• Platform Validation: Each new clinical program reinforces the broader GeneTAC® approach of modulating disease-causing gene expression without gene editing, strengthening the platform’s overall investment thesis.

Find out more about the latest clinical updates and financial reports at the Design Therapeutics investor portal.